Metoclopramide: A novel and safe immunomodulating agent for restoring the depressed macrophage immune function after hemorrhage

Journal of Trauma - Injury, Infection and Critical Care

Volumn 44, Issue 1, 1998, Pages 70-77

  Zellweger, René ^a,b   Wichmann, Matthias W ^a,b   Ayala, Alfred ^a,b   Chaudry, Irshad H ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Corticosterone; Hemorrhage resuscitation; IL 1; IL 2; IL 3; IL 6; Macrophages; Metoclopramide; Splenocyte proliferation; Splenocytes

Indexed keywords

CONCANAVALIN A; CORTICOSTERONE; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; METOCLOPRAMIDE; PROLACTIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; HEMORRHAGIC SHOCK; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DEFICIENCY; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RESUSCITATION; SPLEEN CELL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031905851     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199801000-00006     Document Type: Conference Paper

References (49)

1. Shires GT. Principles and management of hemorrhagic shock. In: Shires GT, ed. Principles of Trauma Care. New York, NY: McGraw-Hill; 1985:3-42.
2. Trunkey DD. Trauma. Sci Am. 1983(Aug);249:28.
3. Ayala A, Ertel W, Chaudry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock. 1996;5:79.
4. Chaudry IH, Ayala A. Immunological Aspects of Hemorrhage. Austin, Tex: Medical Intelligence Unit, RG Landes; 1992.
5. Bernton EW. Prolactin and immune host defenses. Prog Neuroendocr Immunol. 1989;2:21.
6. Zellweger R, Wichmann MW, Ayala A, et al. Prolactin: a novel and safe immunomodulating hormone for the treatment of immunodepression following severe hemorrhage. J Surg Res. 1996;63:53.
7. Berczi I, Nagy E. Prolactin and other lactogenic hormones. In: Berczi I, ed. Pituitary Function and Immunology. Boca Raton, Fla: CRC Press; 1986:168.
8. Ehrenkranz RA, Ackerman BA. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics. 1986;78:614.
9. Guyton AC. Pregnancy and lactation. In: Wonsiewicz MJ, ed. Textbook of Medical Physiology. 8th ed. Philadelphia, Pa: WB Saunders; 1991:926.
10. Gala RR. Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med. 1991;198:513. Minireview.
11. Besedovsky H, Sorkin E. Network of immune-neuroendocrine interactions. Clin Exp Immunol. 1977;27:1.
12. Parrott RF, Goode JA. Central effects of naloxone and selected opioid agonists on cortisol and prolactin secretion in non-stressed sheep. Gen Pharmacol. 1993;24:101.
13. Domanski E, Romanowicz K, Kerdelhu B. Enhancing effect of intracerebrally infused β-endorphin antiserum on the secretion of cortisol in foot-shocked sheep. Neuroendocrinology. 1993;57:127.
14. Stephan RN, Kupper TS, Geha AS, et al. Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg. 1987;122:62.
15. Zellweger R, Ayala A, DeMaso CM, et al. Trauma-hemorrhage causes prolonged depression in cellular immunity. Shock. 1995;4:149.
16. Ihle JN, Keller J, Greenberger JS, et al. Phenotypic characteristics of cell lines requiring IL-3 for growth. J Immunol. 1982;129:1377.
17. Meldrum DR, Ayala A, Perrin MM, et al. Diltiazem restores IL-2, IL-3, IL-6 and IFN-gamma synthesis and decreases susceptibility to sepsis following hemorrhage. J Surg Res. 1991;51:158.
18. Mizel SB. Production and quantitation of lymphocyte-activating factor (interleukin-1). In: Herscowitz HB, Holden HT, Bellanti JA, et al., eds. Manual of Macrophage Methodology. New York, NY: Marcel Dekker; 1981:407-441.
19. Ertel W, Morrison MH, Ayala A, et al. Chloroquine attenuates hemorrhagic shock induced suppression of Kupffer cell antigen presentation and MHC class II antigen expression through blockade of tumor necrosis factor and prostaglandin release. Blood. 1991;78:1781.
20. Hültner L, Szöts H, Welle M, et al. Mouse bone marrow-derived interleukin 3-dependent mast cells and autonomous sublines produce interleukin 6. Immunology. 1989;67:408.
21. Brouwers JRBJ, Assies J, Wiersinga WM, et al. Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Clin Endocrinol. 1980;12:435.
22. Kauppila A, Arvela P, Koivisto M, et al. Metoclopramide and breast feeding: transfer into milk and the newborn. Eur J Clin Pharmacol. 1983;25:819.
23. Gupta AP, Gupta PK. Metoclopramide as a lactagogue. Clin Pediatr. 1985;24:269.
24. Guzman V, Toscano G, Canales ES, et al. Improvement of defective lactation by using oral metoclopramide. Acta Obstet Gynecol Scand. 1979;58:53.
25. Neill JD. Effect of "stress" on serum prolactin and luteinizing hormone levels during the estrous cycle of the rat. Endocrinology. 1970;87:1192.
26. Carlson DE, Klemcke HG, Gann DS. Response of prolactin to hemorrhage is similar to that of adrenocorticotropin in swine. Am J Physiol. 1990;258:R645.
27. Wichmann MW, Zellweger R, DeMaso CM, et al. Enhanced immune responses in females as opposed to decreased responses in males following hemorrhagic shock. Cytokine. 1996;8:853.
28. Margieson GR, Williams HB. Radiopharmacology of the stomach: with special reference to the effects of metoclopramide. Australas Radiol. 1968;12:239.
29. Bruera E, Michaud M, Partington J, et al. Continuous subcutaneous (CS) infusion of metoclopramide (MCP) using a plastic disposable infusor for the treatment of chemotherapy-induced nemesis. J Pain Symptom Manage. 1988;3:105.
30. McCallum RW, Valenzuela G, Polepalle S, et al. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharmacol Exp Ther. 1991;258:136.
31. Margieson GR, Sorby WA, Williams HB. The action of "metoclopramide" on gastric emptying: a radiological assessment. Med J Aust. 1966;2:1272.
32. Zellweger R, Ayala A, Zhu X, et al. A novel nonanticoagulant heparin improves splenocyte and peritoneal macrophage immune function after trauma-hemorrhage and resuscitation. J Surg Res. 1995;59:211.
33. Zellweger R, Zhu X, Wichmann MW, et al. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 1996; 157:5748.
34. Blalock JE. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev. 1989;69:1.
35. Spangelo BL, Hall NRS, Ross PC, et al. Stimulation of in vivo antibody production and Con-A induced mouse spleen mitogenesis by prolactin. Immunopharmacology. 1987;14:11.
36. Nagy E, Berczi I, Wren GE, et al. Immunomodulation by bromocriptine. Immunopharmacology. 1983;6:231.
37. Bernton EW, Meltzer MS, Holaday JW. Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science. 1988;239:401.
38. Russell DH, Kibler R, Matrisian L, et al. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol. 1985;134:3027.
39. Kenner JR, Holaday JW, Bernton EW, et al. Prolactin in murine lymphocytes: morphologic and biochemical evidence. Prog Neuroendocr Immunol. 1990;3:188.
40. Hatfill SJ, Kirby R, Hanley M, et al. Hyperprolactinemia in acute myeloid leukemia and indication of ectopic expression of human prolactin in blast cells of a patient of subtype M4. Leuk Res. 1990;14:57.
41. Rosen SW, Weintraub BD, Aaronson SA. Nonrandomectopic protein production by malignant cells: direct evidence in vitro. J Clin Endocrinol Metab. 1980;50:834.
42. Hiestand PC, Mekler P, Nordman R, et al. Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA. 1986;83:2599.
43. Wilner ML, Ettenger RB, Koyle MA, et al. The effect of hypoprolactinemia alone and in combination with cyclosporine on allograft rejection. Transplantation. 1990; 49:264.
44. Holaday JW, Kenner JR, Smith PF, et al. Neuroendocrine regulation of immune function. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin, Germany: Springer-Verlag; 1993:59-65.
45. Blomgren H, Andersson B. Steroid sensitivity of the PHA and PWM responses of fractionated human lymphocytes in vitro. Exp Cell Res. 1976;97:233.
46. Neifeld JP, Tormey DC. Effects of steroid hormones on phytohemagglutinin-stimulated human peripheral blood lymphocytes. Transplantation. 1979;27:309.
47. Larsson EL. Cyclosporin A and dexamethasone suppress T cell responses by electively acting at distinct sites of the triggering process. J Immunol. 1980;124:2828.
48. Claman HN. Corticosteroid and lymphoid cells. N Engl J Med. 1972;287:388.
49. Lee SW, Tsou AP, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin-1 mRNA. Proc Natl Acad Sci USA. 1988;85:1204.